HK1110512A1 - Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder - Google Patents

Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Info

Publication number
HK1110512A1
HK1110512A1 HK08101377.3A HK08101377A HK1110512A1 HK 1110512 A1 HK1110512 A1 HK 1110512A1 HK 08101377 A HK08101377 A HK 08101377A HK 1110512 A1 HK1110512 A1 HK 1110512A1
Authority
HK
Hong Kong
Prior art keywords
bombesin
gastrin
treatment
inflammatory conditions
bipolar disorder
Prior art date
Application number
HK08101377.3A
Other languages
English (en)
Inventor
Gilberto Schwartsmann
Rafael Roesler
Felip Dal Pizzol
Joao Luciano Quevedo
Flavio Kapczinski
Original Assignee
Cristalia Produtos Quimicos E Farmaceuticos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Produtos Quimicos E Farmaceuticos Ltda filed Critical Cristalia Produtos Quimicos E Farmaceuticos Ltda
Publication of HK1110512A1 publication Critical patent/HK1110512A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Arc Welding In General (AREA)
HK08101377.3A 2004-12-17 2008-02-05 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder HK1110512A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63652504P 2004-12-17 2004-12-17
US74817805P 2005-12-08 2005-12-08
PCT/EP2005/013522 WO2006063837A2 (en) 2004-12-17 2005-12-15 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Publications (1)

Publication Number Publication Date
HK1110512A1 true HK1110512A1 (en) 2008-07-18

Family

ID=35810282

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101377.3A HK1110512A1 (en) 2004-12-17 2008-02-05 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Country Status (13)

Country Link
US (1) US7795385B2 (pt)
EP (1) EP1827476B1 (pt)
JP (1) JP4950903B2 (pt)
CN (2) CN102441157B (pt)
AR (1) AR052996A1 (pt)
BR (1) BRPI0519515A2 (pt)
CA (1) CA2590804C (pt)
ES (1) ES2434943T3 (pt)
HK (1) HK1110512A1 (pt)
MX (1) MX2007007238A (pt)
NO (1) NO20073696L (pt)
TW (1) TWI361694B (pt)
WO (1) WO2006063837A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006143601A (ja) * 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
DE102007005580A1 (de) * 2007-01-23 2008-07-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Sepsis
WO2010101990A1 (en) * 2009-03-04 2010-09-10 Duke University Methods of treating lung disease and other inflammatory diseases
CN103027915A (zh) * 2011-09-29 2013-04-10 中国医学科学院基础医学研究所 氯喹治疗和氯丙嗪预防肺感染和损伤的用途
US20220002399A1 (en) * 2018-09-11 2022-01-06 University Of Maryland, Baltimore Methods for decreasing influenza-induced lethality using gastrin-releasing peptide (grp) inhibitors or gastrin-releasing peptide receptor (grpr) antagonists
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
JPH0853387A (ja) * 1994-08-12 1996-02-27 Sankyo Co Ltd 新規化合物ｆ−１１２６３
US5750370A (en) * 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
WO1998007718A1 (en) * 1996-08-22 1998-02-26 Warner-Lambert Company Non-peptide bombesin receptor antagonists
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
GB2369117A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
GB2369118A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors

Also Published As

Publication number Publication date
AR052996A1 (es) 2007-04-18
TW200635602A (en) 2006-10-16
NO20073696L (no) 2007-09-07
WO2006063837A3 (en) 2007-02-08
CA2590804C (en) 2015-12-22
WO2006063837A8 (en) 2007-08-30
MX2007007238A (es) 2007-07-11
JP2008538098A (ja) 2008-10-09
ES2434943T3 (es) 2013-12-18
CN101090731A (zh) 2007-12-19
CN102441157A (zh) 2012-05-09
US20060160744A1 (en) 2006-07-20
TWI361694B (en) 2012-04-11
CN101090731B (zh) 2012-08-08
JP4950903B2 (ja) 2012-06-13
CA2590804A1 (en) 2006-06-22
US7795385B2 (en) 2010-09-14
EP1827476B1 (en) 2013-08-14
BRPI0519515A2 (pt) 2009-02-25
WO2006063837A2 (en) 2006-06-22
CN102441157B (zh) 2014-05-21
EP1827476A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
IL178402A0 (en) 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
ZA200606056B (en) Selected CGRP antagonists, methods for the production thereof and their use as medicaments
IL178815A0 (en) The treatment of respiratory disease
IL183537A0 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
HK1091732A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
SI1863476T1 (sl) Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
HK1110512A1 (en) Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
IL187248A0 (en) Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
GB0410399D0 (en) The treatment of respiratory disease
IL174303A0 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
HK1079776A1 (en) The synthesis of 1,3-dihydro-2h-3-benzazepin-2-onecompounds, and the use thereof
WO2009006246A8 (en) Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
GB0427568D0 (en) Particle-size reduction apparatus, and the use thereof
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
EP2193789A4 (en) USE OF 3,5-DIHYDROTOLUENE OR ITS DERIVATIVES IN THE PREPARATION OF MEDICINAL PRODUCTS OR FUNCTIONAL FOOD FOR THE TREATMENT OR PREVENTION OF DEPRESSION

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151215